Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Speaker bio
- Content
- Part 1 (Intro)
- Portfolio management in pharmaceutical R&D
- Portfolio management in the pharma industry
- Best practice portfolio management in big pharma
- Evaluation of individual projects
- The five determinants of value
- Net Present Value (NPV) equation
- Financial project evaluation
- Sources of risk
- How to calculate NPVs
- Attrition rates & reasons for failure in R&D
- R&D risk management
- Commercial risks
- Sales forecast (15 trials in Monte Carlo simulation)
- Monte Carlo simulation: frequency histogram
- Added value per completed milestone
- Getting to valid assumptions and good decisions
Topics Covered
- Portfolio management in pharmaceutical R&D and industry
- Best practice portfolio management in big pharma
- Evaluation of individual projects
- The five determinants of value
- Net Present Value (NPV) equation
- Financial project evaluation
- Sources of risk
- How to calculate NPVs
- Attrition rates & reasons for failure in R&D
- R&D risk management
- Commercial risks
- Sales forecast (15 trials in Monte Carlo simulation)
- Monte Carlo simulation: frequency histogram
- Added value per completed milestone
- Getting to valid assumptions and good decisions
Talk Citation
Greuel, J.M. (2017, March 29). Portfolio planning and risk management in the pharmaceutical industry 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/YABM3559.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Joachim M. Greuel has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Portfolio planning and risk management in the pharmaceutical industry 1
Published on March 29, 2017
53 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
I am Joachim Greuel,
Managing Director at Bioscience Valuation,
a company engaged in portfolio management
and risk management as well.
And I'm going to talk about
Portfolio Planning
and Risk Management
in the Pharmaceutical Industry.
0:21
Before I begin, a few words about myself,
I studied biology in Germany and in the UK,
and received a PhD in neuroscience
from the Max-Planck-Institute
for Brain Research.
I also hold an MBA
from the Wharton School of the University
of Pennsylvania in the US
with a healthcare management
and finance focus.
I also served as academic director
and professor
at the IE Business School in Madrid,
teaching courses related to pharmacoeconomics
and also related to portfolio managements
in the pharmaceutical industry.
Before I co-founded Bioscience Valuation
more than 18 years ago,
I worked for Bayer Pharmaceuticals
as head of a research group
for couple of years
and also as investment manager
for a venture capital fund in Switzerland.
1:21
The presentation is divided into four parts.
I will start with a short introduction
and then move on to the evaluation
of individual projects.
The evaluation of individual projects
is a prerequisite for portfolio management.
The third part will talk about
portfolio planning and risk management,
and the final section will focus on project
and portfolio value maximization.
Hide